XRAY vs. NVST, IONS, ACHC, PCVX, RVMD, ELAN, APLS, ENSG, HQY, and CYTK
Should you be buying DENTSPLY SIRONA stock or one of its competitors? The main competitors of DENTSPLY SIRONA include Envista (NVST), Ionis Pharmaceuticals (IONS), Acadia Healthcare (ACHC), Vaxcyte (PCVX), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Apellis Pharmaceuticals (APLS), The Ensign Group (ENSG), HealthEquity (HQY), and Cytokinetics (CYTK). These companies are all part of the "medical" sector.
DENTSPLY SIRONA (NASDAQ:XRAY) and Envista (NYSE:NVST) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment.
DENTSPLY SIRONA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Envista has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500.
95.7% of DENTSPLY SIRONA shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 1.3% of Envista shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
DENTSPLY SIRONA has a net margin of -3.33% compared to Envista's net margin of -3.90%. DENTSPLY SIRONA's return on equity of 11.14% beat Envista's return on equity.
DENTSPLY SIRONA received 426 more outperform votes than Envista when rated by MarketBeat users. Likewise, 61.38% of users gave DENTSPLY SIRONA an outperform vote while only 40.30% of users gave Envista an outperform vote.
Envista has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
In the previous week, DENTSPLY SIRONA had 1 more articles in the media than Envista. MarketBeat recorded 8 mentions for DENTSPLY SIRONA and 7 mentions for Envista. DENTSPLY SIRONA's average media sentiment score of 0.75 beat Envista's score of 0.59 indicating that DENTSPLY SIRONA is being referred to more favorably in the media.
DENTSPLY SIRONA presently has a consensus target price of $39.50, suggesting a potential upside of 30.36%. Envista has a consensus target price of $27.90, suggesting a potential upside of 41.55%. Given Envista's higher probable upside, analysts clearly believe Envista is more favorable than DENTSPLY SIRONA.
Summary
DENTSPLY SIRONA beats Envista on 12 of the 18 factors compared between the two stocks.
Get DENTSPLY SIRONA News Delivered to You Automatically
Sign up to receive the latest news and ratings for XRAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XRAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
DENTSPLY SIRONA Competitors List
Related Companies and Tools